Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma

Final draft guidance

Final draft guidance (PDF 273 KB)

Committee papers (PDF 2.25 MB)

Public committee slides (PDF 647 KB)

Equality impact assessment (PDF Version) (PDF 313 KB)

Draft guidance

Committee papers (PDF 9.64 MB)

Appraisal consultation document (PDF version) (PDF 307 KB)

Appraisal consultation document (online commenting)

Public committee slides (PDF 1.61 MB)

Draft guidance (PDF version) Equality impact assessment - guidance development (PDF 320 KB)

Committee meeting: 2

Supporting documentation Register of interests (PDF 336 KB)

Final scope (PDF 207 KB)

Final stakeholder list (PDF 167 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 157 KB)

Equality impact assessment (Scoping) (PDF 127 KB)

Register of interests (MSWord 41 KB)

Draft matrix post referral (PDF 164 KB)

Draft scope post referral (PDF 196 KB)